Top entities: FiberSense, Novartis, European Union, Michael Mann.

What category does this event fall under?

Regulatory — classified as regulatory approval.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory regulatory approval

FiberSense CGM System CE Mark

Q: When did this event occur?

First reported Jun 17, 2026; last updated Jun 17, 2026.

Q: What is the market impact?

General. The CE marking for FiberSense's CGM System is expected to positively impact the medical device market, particularly in diabetes management, by introducing a new long-wear monitoring solution.

Analysis based on 8 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The CE marking for FiberSense's CGM System is expected to positively impact the medical device market, particularly in diabetes management, by introducing a new long-wear monitoring solution. This could lead to increased competition and innovation in the continuous glucose monitoring sector, potentially affecting other companies in this space.

Medical Devices Healthcare

Event Summary

FiberSense, a Swiss optical biomarker sensing company, has achieved a major regulatory milestone by obtaining CE marking for its Continuous Glucose Monitoring (CGM) System under Regulation (EU) 2017/745. This certification allows FiberSense to commercialize its Class IIb medical device, intended for continuous monitoring of blood sugar levels in adults with diabetes, within the European Union. Michael Mann, Chairman & CEO, emphasized that this approval is a defining moment, shifting the company's focus to manufacturing scale-up and commercialization, with initial deliveries anticipated in late 2026. The CGM System, based on advanced optical sensing technology, features a sensor and overtape that can be worn for up to 28 days. This marks the first regulated application of FiberSense's broader continuous multi-analyte (CxM) platform strategy, with future plans to explore sensing for ketones, lactate, and cortisol.

Entities Involved

priv

FiberSense

FiberSense obtained CE marking for its Continuous Glucose Monitoring (CGM) System, a significant regulatory milestone that paves the way for commercialization and manufacturing scale-up. This approval is crucial for the company's market entry and future growth in biomarker sensing.

Importance 100.0 Sentiment 75.0

stock

Novartis

Novartis is mentioned as the former parent company of CIBA Vision, from which EyeSense, a spin-off, originated. This provides historical context for FiberSense's expertise but does not indicate a direct impact from this event.

Importance 10.0 Sentiment 0.0

alliance

European Union

Importance 0.0 Sentiment 0.0

per

Michael Mann

Importance 0 Sentiment 0

Relationships

European Union related ↔ Michael Mann

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard